Implication of bone regulatory factors in human coronary artery calcification

Artery Research

Volumn 5, Issue 3, 2011, Pages 101-108

  Alexopoulos, Alexandros ^a   Peroukides, Stavros ^a   Bravou, Vasiliki ^a   Varakis, John ^a   Pyrgakis, Vlassios ^b   Papadaki, Helen ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b G GENNIMATAS GENERAL HOSPITAL   (Greece)

Author keywords

Artery; Bone; Calcification; Coronary

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BONE REGULATORY FACTOR; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FORMALDEHYDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIFICATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; INTIMA; MAJOR CLINICAL STUDY; MALE; MINERALIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; TUNICA MEDIA;

EID: 80051945048     PISSN: 18729312     EISSN: 18764401     Source Type: Journal    
DOI: 10.1016/j.artres.2011.06.003     Document Type: Article

References (50)

1. Steitz S.A., Speer M.Y., Curinga G., Yang H.Y., Haynes P., Aebersold R., et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001, 89:1147-1154.
2. Dhore C.R., Cleutjens J.P.M., Lutgens E., Cleutjens K., Geusens P.P.M., Kitslaar P.J., et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001, 21:1998-2003.
3. Mody N., Tintut Y., Radcliff K., Demer L.L. Vascular calcification and its relation to bone calcification: possible underlying mechanisms. J Nucl Cardiol 2003, 10:177-183.
4. Vattikuti R., Towler D.A. Osteogenic regulation of vascular calcification: an early perspective. Am J Physiol Endocrinol Metab 2004, 286:E686-E696.
5. Bobryshev Yuri V. Transdifferentiation of smooth muscle cells into chondrocytes in atherosclerotic arteries in situ: implications for diffuse intimal calcification. J Pathol 2005, 205:641-650.
6. Tyson K.L., Reynolds J.L., McNair R., Zhang Q., Weissberg P.L., Shanahan C.M. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 2003, 23:489-494.
7. Tanaka S., Nakamura K., Takahasi N., Suda T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 2005, 208:30-49.
8. Schoppet M., Al-Fakhri N., Franke F.E., Katz N., Barth P.J., Maisch B., et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-{kappa} B ligand in Monckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 2004, 89:4104-4112.
9. Kiechl S., Schett G., Wenning G., Redlich K., Oberhollenzer M., Mayr A., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004, 109:2175-2180.
10. Orita Y., Yamamoto H., Kohno N., Sugihara M., Honda H., Kawamata S., et al. Role of osteoprotegerin in arterial calcification: development of new animal model. Arterioscler Thromb Vasc Biol 2007, 27:2058-2064.
11. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004, 95:1046-1057.
12. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999, 96:3540-3545.
13. Fujita T., Azuma Y., Fukuyama R., Hattori Y., Yoshida C., Koida M., et al. Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. J Cell Biol 2004, 166:85-95.
14. Hinoi E., Fujimori S., Wang L., Hojo H., Uno K., Yoneda Y. Nrf2 negatively regulates osteoblast differentiation via interfering with Runx2-dependent transcriptional activation. J Biol Chem 2006, 281:18015-18024.
15. Meury T., Verrier S., Alini M. Human endothelial cells inhibit BMSC differentiation into mature osteoblasts in vitro by interfering with osterix expression. J Cell Biochem 2006, 98:992-1006.
16. Tu Q., Valverde P., Chen J. Osterix enhances proliferation and osteogenic potential of bone marrow stromal cells. Biochem Biophys Res Commun 2006, 341:1257-1265.
17. Akiyama H., Chaboissier M.C., Martin J.F., Schedl A., de Crombrugghe B. The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev 2002, 16:2813-2828.
18. Akiyama H., Chaboissier M.C., Behringer R.R., Rowitch D.H., Schedl A., Epstein J.A., et al. Essential role of Sox9 in the pathway that controls formation of cardiac valves and septa. Proc Natl Acad Sci U S A 2004, 101:6502-6507.
19. Lincoln J., Kist R., Scherer G., Yutzey K.E. Sox9 is required for precursor cell expansion and extracellular matrix organization during mouse heart valve development. Dev Biol 2007, 305:120-132.
20. Nakashima K., Zhou X., Kunkel G., Zhang Z., Deng J.M., Behringer R.R., et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002, 108:17-29.
21. Qu G., von Schroeder H.P. Role of osterix in endothelin-1-induced downregulation of vascular endothelial growth factor in osteoblastic cells. Bone 2006, 38:21-29.
22. Kim Y.J., Kim H.N., Park E.K., Lee B.H., Ryoo H.M., Kim S.Y., et al. The bone-related Zn finger transcription factor Osterix promotes proliferation of mesenchymal cells. Gene 2006, 366:145-151.
23. Horsley V., Pavlath G.K. NFAT: ubiquitous regulator of cell differentiation and adaptation. J Cell Biol 2002, 156:771-774.
24. Serfling E., Chuvpilo S., Liu J. H fer T and Palmetshofer A. NFATc1 autoregulation: a crucial step for cell-fate determination. Trends Immunol 2006, 27:461-469.
25. Koga T., Matsui Y., Asagiri M., Kodama T., de Crombrugghe B., Nakashima K., et al. NFAT and Osterix cooperatively regulate bone formation. Nat Med 2005, 11:880-885.
26. Horne W.C., Sanjay A., Bruzzaniti A., Baron R. The role (s) of Src kinase and Cbl proteins in the regulation of osteoclast differentiation and function. Immunol Rev 2005, 208:106-125.
27. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268.
28. Mizuno A., Amizuka N., Irie K., Murakami A., Fujise N., Kanno T., et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998, 247:610-615.
29. Schoppet M., Preissner K.T., Hofbauer L.C. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002, 22:549-553.
30. Engelse M.A., Neele J.M., Bronckers A., Pannekoek H., de Vries C.J.M. Vascular calcification: expression patterns of the osteoblast-specific gene core binding factor {alpha}-1 and the protective factor matrix gla protein in human atherogenesis. Cardiovasc Res 2001, 52:281-289.
31. Geske J.B., Edwards W.D., MacDonald R.J., Holmes D.R. Location of coronary culprit lesions at autopsy in 41 nondiabetic patients with acute myocardial infarction. Am J Forensic Med Pathology 2010, 31:213-217.
32. Kolodgie F.D., Virmani R., Burke A.P., Farb A., Weber D.K., Kutys R., et al. Pathologic assessment of the vulnerable human coronary plaque. Heart 2004, 90:1385-1391.
33. Ha E.J., Kim Y., Cheung J.Y., Shim S.S. Coronary artery disease in asymptomatic Young Adults: its prevalence according to coronary artery disease risk stratification and the CT. Characteristics Korean J Radiol 2010, 11:425-432.
34. Stary H.C., Chandler A.B., Dinsmore R.E., Fuster V., Glagov S., Insull W., et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the committee on Vascular Lesions of the council on arteriosclerosis, American Heart Association. Circulation 1995, 92:1355-1374.
35. Alexopoulos A., Bravou V., Peroukides S., Kaklamanis L., Varakis J., Alexopoulos D., et al. Bone regulatory factors NFATc1 and Osterix in human calcific aortic valves. Int J Cardiol 2010, 139:142-149.
36. Babiarz L.S., Yousem D.M., Bilker W., Wasserman B.A. Middle cerebral artery infarction: Relationship of cavernous carotid artery calcification. AJNR Am J Neuroradiol 2005, 26:1505-1511.
37. Trion A., van der Laarse A. Vascular smooth muscle cells and calcification in atherosclerosis. Am Heart J 2004, 147:808-814.
38. Collin-Osdoby P., Rothe L., Anderson F., Nelson M., Maloney W., Osdoby P. Receptor activator of NF-κB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001, 276:20659-20672.
39. Kaden J.J., Bickelhaupt S., Grobholz R., Haase K.K. Receptor activator of nuclear factor [kappa] B ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 2004, 36:57-66.
40. Min H., Morony S., Sarosi I., Dunstan C.R., Capparelli C., Scully S., et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000, 192:463-474.
41. Kaji H., Kanatani M., Sugimoto T., Chihara K. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures. Horm Metab Res 2005, 37:589-592.
42. Li H., Tao H., Hu T., Fan Y., Zhang R., Jia G., et al. Atorvastatin reduced calcification in rat arteries and vascular smooth muscle cells. Basic Clin Pharm Toxicol 2010, 107:798-802.
43. Crotti T., Smith M.D., Hirsch R., Soukoulis S., Weedon H., Capone M., et al. Receptor activator NF κB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res 2003, 38:380-387.
44. Haynes D.R., Barg E., Crotti T.N., Holding C., Weedon H., Atkins G.J., et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology 2003, 42:123-134.
45. Jono S., Ikari Y., Shioi A., Mori K., Miki T., Hara K., et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002, 106:1192-1194.
46. Ziegler S., Kudlacek S., Luger A., Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 2005, 182:175-180.
47. Helske S., Kovanen P.T., Lindstedt K.A., Salmela K., Lommi J., Turto H., et al. Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. Eur J Heart Fail 2007, 9:357-363.
48. Crotti T.N., Flannery M., Walsh N.C., Fleming J.D., Goldring S.R., McHugh K.P. NFATc1 regulation of the human β3 integrin promoter in osteoclast differentiation. Gene 2006, 372:92-102.
49. Grines C.L. The role of statins in reversing atherosclerosis: what the latest regression studies show. J Interv Cardiol 2006, 19:3-9.
50. Higgins J.P. Can angiotensin-converting enzyme inhibitors reverse atherosclerosis?. South Med J 2003, 96:569-579.